管理委员会总裁兼首席执行官JožeColarič解释说:‘Krka集团在2024年继续成功的业务运营。我们记录了自成立以来最强劲的销售,并看到大多数市场的销售额在东欧地区最大的销售额增长。我们记录了估计的营业利润(EBIT)为4.27亿欧元,增长了7%,估计净利润为3.534亿欧元,上涨了4000万欧元或13%。我们获得了22种新产品的营销授权,并在各个国家 /地区完成了1,000多种营销授权程序,扩展了我们的产品组合并增加了治疗的可用性。KRKA集团投资总计1.17亿欧元。我们将它们分配给了生产技术,开发和质量的改进,增强了我们垂直整合的商业模型的关键要素。
14.1.1。emtricitabine,Tenofovir disoproxil -Emtricerabine/Tenofovir disoproxil Krka,Emtricitabine/Tenofovir disoproxil Krka D.D. ......................................................................................................................................................................................................................................................
GDP - 国内生产总值 - 中央处理单元CSF - 脑脊液DG Energ - 能源DMP的总局 - 能源DMP总局 - 数据管理计划EBI - 欧洲生物信息学研究所ESFRI - 欧洲生物信息学院ESFRI - 欧洲策略论坛ERIC - ERIC - ERIC - 欧洲研究基金会及欧洲社会基金会 - 欧洲融合 - 欧洲融合 - 欧洲融合 - 欧洲融合 - 欧洲融合 - 欧洲互联网 - 欧洲交流 - 欧洲融合 - 全日制等效GB - 千兆gpgpu - 通用图形处理单元h-index - Hirsch index hamag-bicro - hrvatska agencija za za za malo goppodarstvo,inovacije i InvestiCije I Investionicije I Investionicije,Croatian for Croatian for Croatian for smes and Investion,Information and Invorys kun kun kun kun kun kun kun krka krk krka krka krk krk krk krka技术RDI - 研究,开发,创新ITER - 国际热核实验反应器MZO - Ministarstvo Znanosti I Obrazovanja,科学与教育部Ni4os Europe - 国家公开科学的国家开放科学倡议用于研究与创新(2014- 2020年)OPCC - 运营计划的竞争力和凝聚力2021–2027 R&D - 研究与发展RI - 研究基础设施S3 - 智能专业策略2021–2029 SMP - 对称对称性 - 对称对称性,TB - TB - TERBYTE UNITIAL ZCI ZCI -ZCI -ZNANANIN -ZNANANANANANANANANANANANANECVERISCENTRIS IMESTER
摘要:洪泛区修复措施是降低风险的最著名的解决方案之一,但是从业者在考虑其有效性和利用性时,与技术措施相比,其局限性。这项研究的目的是显示流量恢复的共同利益(除了降低风险降低风险,并根据货币化的生态系统服务(ES)处理它们。我们的工作集中在Krka,Morava和Danube Rivers沿线的多瑙河集水区的三个研究区域。映射。我们应用了工具包中建议的基于生态系统服务网站评估(TESSA)的方法,并辅以替代方法(例如,社交媒体上的问卷)。结果表明,年度的浮游恢复的综合收益范围从2019年的237,000美元在KRKA到2019年在Morava的310万美元,这表明ES评估的实用性。利益相关者研讨会和TESSA指南以及新开发的方法的结合都是为决策者提供基于自然解决方案的参数,以进行基于自然的解决方案进行综合和整体河岸土地利用管理。
包装说明书: Enroxil 15 mg 狗猫调味片剂 Enroxil 调味 15 mg 狗猫片剂 1. 营销授权持有人和制造商的名称和永久地址(如不同) 营销授权持有人和负责批次放行的制造商: KRKA, dd, Novo mesto Šmarješka cesta 6 8501 Novo mesto 斯洛文尼亚 2. 兽药名称 Enroxil 15 mg 狗猫调味片剂 恩诺沙星 恩诺沙星 3. 活性物质和辅料的声明 每片含 15 mg 恩诺沙星。圆形、略双凸、乳白色至略带棕色的药片,可能有可见的白色或深色斑点和斜边。 4. 治疗指征 当临床经验确定恩诺沙星为合适的药物时,该药物用于治疗狗和猫的消化道、呼吸道和泌尿生殖道、皮肤、继发性伤口感染和外耳炎的细菌感染。 5. 禁忌症 请勿用于年龄小于1岁的狗或年龄小于18个月且生长期较长的超大型犬,因为在快速生长期关节软骨可能会受损。请勿用于 8 周以下的猫。如果狗/猫对活性物质或任何赋形剂过敏,请勿使用。请勿对患有癫痫的狗使用,因为恩诺沙星可能会引起中枢神经系统刺激。请勿用于预防。 6.不良反应在快速生长期间,恩诺沙星可能会影响关节软骨的发育。
利益冲突:K.P。收到了三菱Tanabe Pharma的讲座费。N.V.C. 获得了R-Biopharm,Takeda和UCB的研究赠款和个人费用;以及Alimentiv,Inc。(以前是Robarts Clinical Trials,Inc。)的个人费用,Celltrion和Prometheus。 A.S.C:收到了Abbvie,Janssen,Takeda,Bacainn,Arena Pharmaceuticals,Grifols,Prometheus,Samsung,Bristol Myers Squibb和Pfizer和Pfizer以及Inform诊断的研究支持。 s.v. 获得了Abbvie,J&J,Pfizer和Takeda的赠款;并已收到Abbvie,Arena Pharmaceuticals,Avaxia,Boehringer Ingelheim,Celgene,Celgene,Falk Pharma博士,Falk Pharma,Ferring,Galapagos,Galapagos,Gelentech-Roche,Gilead,Gilead,Hospira,Hospira,Hospira,Hospira,Janssen,Janssen,Janssen,Mundipharma,Msdipharma,Progigest,Promise,Promise,Promise,Promise,promister,promigen,promigen,promigen,promigen,promigen,promigen,基因组,郡,武田,Theravance和Tilots Pharma ag。 N.A. 从辉瑞(Pfizer)获得了赠款,并从辉瑞(Pfizer)和武田(Takeda)获得了詹森(Janssen)的演讲费。 T.K. 报告了Alfresa Pharma,Covidien,Eli Lilly,Ferring Pharmaceuticals,Janssen,Kyorin Pharmaceutical,Mochida Pharmaceutical,Nippon kyaku,pfizer,Takeda Pharmaceutical,Themo Scientific,Abbvie GK,Abbvie GK,Astrace of Pronmach,Nippare,Nippare,EA,EA KYA,EA KYA,EA KYAAK,NIPPON,EA KYAAK,NIPPON PHARMATICAN,NIPPON PHARMATICATIC三菱Tanabe Pharma,Zeria,Gilead Sciences,Janssen,Jimro,Abbvie GK,EA Pharma,Otsuka Holdings,Zeria,Kyorin Pharmaceutical,Mochida Pharmaceutical,Thermo Fisher,Thermo Fisher Scientific,Alfresa Pharma,Nippon Kyaku。 p.m.i. M.F. P.G.K. N.K. 已从Janssen获得发言人费用。 W.A. A.J.Y.N.V.C.获得了R-Biopharm,Takeda和UCB的研究赠款和个人费用;以及Alimentiv,Inc。(以前是Robarts Clinical Trials,Inc。)的个人费用,Celltrion和Prometheus。A.S.C:收到了Abbvie,Janssen,Takeda,Bacainn,Arena Pharmaceuticals,Grifols,Prometheus,Samsung,Bristol Myers Squibb和Pfizer和Pfizer以及Inform诊断的研究支持。s.v.获得了Abbvie,J&J,Pfizer和Takeda的赠款;并已收到Abbvie,Arena Pharmaceuticals,Avaxia,Boehringer Ingelheim,Celgene,Celgene,Falk Pharma博士,Falk Pharma,Ferring,Galapagos,Galapagos,Gelentech-Roche,Gilead,Gilead,Hospira,Hospira,Hospira,Hospira,Janssen,Janssen,Janssen,Mundipharma,Msdipharma,Progigest,Promise,Promise,Promise,Promise,promister,promigen,promigen,promigen,promigen,promigen,promigen,基因组,郡,武田,Theravance和Tilots Pharma ag。N.A.从辉瑞(Pfizer)获得了赠款,并从辉瑞(Pfizer)和武田(Takeda)获得了詹森(Janssen)的演讲费。T.K. 报告了Alfresa Pharma,Covidien,Eli Lilly,Ferring Pharmaceuticals,Janssen,Kyorin Pharmaceutical,Mochida Pharmaceutical,Nippon kyaku,pfizer,Takeda Pharmaceutical,Themo Scientific,Abbvie GK,Abbvie GK,Astrace of Pronmach,Nippare,Nippare,EA,EA KYA,EA KYA,EA KYAAK,NIPPON,EA KYAAK,NIPPON PHARMATICAN,NIPPON PHARMATICATIC三菱Tanabe Pharma,Zeria,Gilead Sciences,Janssen,Jimro,Abbvie GK,EA Pharma,Otsuka Holdings,Zeria,Kyorin Pharmaceutical,Mochida Pharmaceutical,Thermo Fisher,Thermo Fisher Scientific,Alfresa Pharma,Nippon Kyaku。 p.m.i. M.F. P.G.K. N.K. 已从Janssen获得发言人费用。 W.A. A.J.Y.T.K.报告了Alfresa Pharma,Covidien,Eli Lilly,Ferring Pharmaceuticals,Janssen,Kyorin Pharmaceutical,Mochida Pharmaceutical,Nippon kyaku,pfizer,Takeda Pharmaceutical,Themo Scientific,Abbvie GK,Abbvie GK,Astrace of Pronmach,Nippare,Nippare,EA,EA KYA,EA KYA,EA KYAAK,NIPPON,EA KYAAK,NIPPON PHARMATICAN,NIPPON PHARMATICATIC三菱Tanabe Pharma,Zeria,Gilead Sciences,Janssen,Jimro,Abbvie GK,EA Pharma,Otsuka Holdings,Zeria,Kyorin Pharmaceutical,Mochida Pharmaceutical,Thermo Fisher,Thermo Fisher Scientific,Alfresa Pharma,Nippon Kyaku。p.m.i. M.F. P.G.K. N.K. 已从Janssen获得发言人费用。 W.A. A.J.Y.p.m.i.M.F. P.G.K. N.K. 已从Janssen获得发言人费用。 W.A. A.J.Y.M.F.P.G.K. N.K. 已从Janssen获得发言人费用。 W.A. A.J.Y.P.G.K.N.K. 已从Janssen获得发言人费用。 W.A. A.J.Y.N.K.已从Janssen获得发言人费用。W.A.A.J.Y.A.J.Y.W. J. S. reports: research grants from Abbvie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda, Theravance Biopharma; consulting fees from Abbvie, Abivax, Admirx, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Bausch Health (Salix), Beigene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston药物,Bristol Meyers Squibb,Celgene,细胞训练,细胞,Cosmo Pharmaceuticals,Escalier Biosciences,Equillium,Equillium,Forbion,Genentech/Roche,Gilead Sciences,Glenmark Sciences,Glenmark Pharmaceuticals,Gossamer Bio,Gossamer Bio,Gossamer Bio,Immunic(Immunic Pharmace) Kyverna Therapeutics, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Provention Bio, Reistone Biopharma, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity治疗剂,苏格达,武术,Theravance Biopharma,Thetis Pharmaceuticals,Tillotts Pharma,UCB,Vendata Biosciences,Ventyx Biosciences,Vimalan Biosciences,Vimalan Biosciences,Vivelix Pharmaceuticals,Vivreon Biosciences,Vivreon Biosciences,Zealand Pharma;以及来自Allakos,Beigene,Gossamer Bio,Oppilan Pharma,Prometheus Biosciences,Prometheus Laboratories Gropenity,Shoreline Biosciences,Ventyx Biosciences,Vimalan Biosciences,Vimalan Biosciences,Vivreon Biosciences的股票或股票期权。从Abvie,Janssen,Pfizer,Takeda,Ferring,Novartis,Novartis和Takeda和Pfizer的科学赠款中获得了咨询和演讲费。配偶:Iveric Bio-顾问,股票期权;后代 - 股票; Oppilan Pharma-顾问,股票期权; Prometheus Biosciences-员工,股票,股票期权;普罗米修斯实验室 - 股票,股票期权,顾问; Ventyx Biosciences - 股票,股票期权; Vimalan Biosciences - 股票,股票期权。报告了Abbvie,BMS,Celgene,Falk Pharma,Ferring,Gilead,MSD,Janssen,Janssen,Janssen,Pfizer,Takeda,Takeda,Theotts,Sapphire Medical,Sandoz,Shire,Warner Chilcott,Warner Chilcott,MSD,Pfizer,Takeeda和AbbBBBBBBBBBBBBBBB,GILA,GILE,GILE,GILE,GILA,GILE,GILE,sanire,sandoz,sandoz,sandoz,sandoz,sandoz,sandoz,sandoz医学, Janssen,Lilly,MSD,Pfizer,Pharmacosmos,Procise,Prometheus,Roche,Sandoz,Samsung Bioepis,Takeda,Topivert,Topivert,VH2,Vifor Pharma,Warner Chilcott。reports financial support for research from Abbvie, Amgen, Biogen, Janssen, Pfizer, and Takeda, consultancy fees from Abbvie, Boehringer-Ingelheim, Celltrion, Janssen, Lilly, Medtronic, MSD, Pfizer, Sandoz, Takeda and Thermo Fisher and speakers fees from Abbvie, Amgen, Biogen, Boehringer-ingelheim,Falk,Ferring,Janssen,Lamepro,MSD,Mylan,Pfizer,Sandoz,Takeda和Truvion Healthcare。D. D.曾担任MSD,Abbvie,Takeda,Pfizer,Janssen,Amgen,Biogen和Krka的发言人,顾问和顾问委员会成员。J.L received unrestricted grants from AbbVie, Almirall, Celgene, Eli Lilly, Janssen-Cilag, LEO Pharma, Novartis, UCB, speaker fees for AbbVie, Almirall, BMS, Janssen-Cilag, Pfizer, UCB and consultant fees for AbbVie, BMS, Celgene, Eli Lilly, Janssen-Cilag, LEO Pharma,Novartis和UCB。从Abbvie,Amgen,Arena Pharmaceuticals,Dynacare,Janssen,Merck,Novartis,Novartis,Pfizer,Sandoz,Takeda获得了咨询费。S.D.S.D.已从Prometheus Labs,Takeda,Arena Pharmaceuticals和Bristol Myers Squibb获得顾问/顾问委员会费用。曾担任Schering-plow,Abbvie,MSD,UCB Pharma,Ferring,Ferring,Cellerix,Cellerix,Takeda,Nycomed,Pharmacosmos,Actelion,Actelion,Actelion,Actelion,Actelion,Actelerman,Alphawasserman,Genentech,Genentech,Grunenthal,Pfizer,Pfizer,Pfizer and vocm andocm andocm andocm andocm and vocm,约翰逊(Johnson),尼克索(Nikkiso)欧洲Gmbh,Theravance。M.C.D. 从Janssen,Abbvie,Pfizer,Takeda,UCB,Celgene,BMS,Prometheus Biosciences,Arena,Lilly,Lilly和Abbvie,Abbvie,Pfizer,Janssen获得了顾问费。 L.P-B: grant support from AbbVie, MSD, Takeda, consulting fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan,MSD,Roche,Arena,Gilead,Hikma,Amga,Amgr,BMS,Vifor,Norgine; Mylan,Lilly,Fresenius,Oppilan Pharma,Sublimity Therapeutics,应用分子运输,OSE免疫治疗药,Enthera以及CTMA的股票或股票期权。 其余的作者没有什么可披露的。M.C.D.从Janssen,Abbvie,Pfizer,Takeda,UCB,Celgene,BMS,Prometheus Biosciences,Arena,Lilly,Lilly和Abbvie,Abbvie,Pfizer,Janssen获得了顾问费。L.P-B: grant support from AbbVie, MSD, Takeda, consulting fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan,MSD,Roche,Arena,Gilead,Hikma,Amga,Amgr,BMS,Vifor,Norgine; Mylan,Lilly,Fresenius,Oppilan Pharma,Sublimity Therapeutics,应用分子运输,OSE免疫治疗药,Enthera以及CTMA的股票或股票期权。其余的作者没有什么可披露的。